Willemien van de Water1, Esther Bastiaannet1, Kathleen M Egan2, Anton J M de Craen3, Rudi G J Westendorp3, Lodovico Balducci4, Cornelis J H van de Velde5, Gerrit-Jan Liefers5, Martine Extermann6. 1. Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands; Department of Geriatrics and Gerontology, Leiden University Medical Center, Leiden, The Netherlands. 2. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. 3. Department of Geriatrics and Gerontology, Leiden University Medical Center, Leiden, The Netherlands. 4. Department of Senior Adult Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. 5. Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands. 6. Department of Senior Adult Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. Electronic address: Martine.Extermann@moffitt.org.
Abstract
BACKGROUND: An oncogeriatric approach may affect management of elderly patients with breast cancer. However, little is known about oncogeriatric care in the metastatic setting. Therefore, we performed an international comparison of management of elderly patients with primary metastatic disease who were treated in two different care settings. MATERIALS AND METHODS: Patients who were ≥70years at diagnosis of primary metastatic disease were eligible. The first cohort comprised a population-based cohort of 104 patients (Comprehensive Cancer Center West, The Netherlands), who all received standard care. The second cohort comprised a hospital-based cohort of 42 patients (H. Lee Moffitt Cancer Center, Florida, United States), who all received oncogeriatric care. RESULTS: No large differences in patient and tumor characteristics were observed between both cohorts. Most patients in the standard care cohort received systemic therapy as primary therapy, whereas most patients in the oncogeriatric cohort received a combination of systemic and local therapy. Patients in the standard care cohort received fewer lines of treatment (mean number of treatments 2.1 vs. 3.6, p<0.001), and particularly received less breast surgery, chemotherapy, and trastuzumab. Three-year overall mortality was 71% (95% CI: 61-83%) as compared to 58% (95% CI: 42-75%) among patients in the oncogeriatric care cohort (multivariable HR: 1.59 [95% CI: 0.88-2.87], p=0.125). CONCLUSIONS: In primary metastatic breast cancer, oncogeriatric care intensifies treatment and might improve survival in elderly patients. Future studies on a larger scale should investigate the potential for improved survival, and whether this is accompanied by a better (preservation of) quality of life and functional status.
BACKGROUND: An oncogeriatric approach may affect management of elderly patients with breast cancer. However, little is known about oncogeriatric care in the metastatic setting. Therefore, we performed an international comparison of management of elderly patients with primary metastatic disease who were treated in two different care settings. MATERIALS AND METHODS:Patients who were ≥70years at diagnosis of primary metastatic disease were eligible. The first cohort comprised a population-based cohort of 104 patients (Comprehensive Cancer Center West, The Netherlands), who all received standard care. The second cohort comprised a hospital-based cohort of 42 patients (H. Lee Moffitt Cancer Center, Florida, United States), who all received oncogeriatric care. RESULTS: No large differences in patient and tumor characteristics were observed between both cohorts. Most patients in the standard care cohort received systemic therapy as primary therapy, whereas most patients in the oncogeriatric cohort received a combination of systemic and local therapy. Patients in the standard care cohort received fewer lines of treatment (mean number of treatments 2.1 vs. 3.6, p<0.001), and particularly received less breast surgery, chemotherapy, and trastuzumab. Three-year overall mortality was 71% (95% CI: 61-83%) as compared to 58% (95% CI: 42-75%) among patients in the oncogeriatric care cohort (multivariable HR: 1.59 [95% CI: 0.88-2.87], p=0.125). CONCLUSIONS: In primary metastatic breast cancer, oncogeriatric care intensifies treatment and might improve survival in elderly patients. Future studies on a larger scale should investigate the potential for improved survival, and whether this is accompanied by a better (preservation of) quality of life and functional status.
Authors: O Feher; P Vodvarka; J Jassem; G Morack; S H Advani; K S Khoo; D C Doval; S Ermisch; D Roychowdhury; M A Miller; G von Minckwitz Journal: Ann Oncol Date: 2005-04-08 Impact factor: 32.976
Authors: Alice B Kornblith; Margaret Kemeny; Bercedis L Peterson; Judith Wheeler; Jeffrey Crawford; Nancy Bartlett; Gini Fleming; Stephen Graziano; Hyman Muss; Harvey Jay Cohen Journal: Cancer Date: 2002-09-01 Impact factor: 6.860
Authors: Martine Extermann; Julie Meyer; Margaret McGinnis; Theresa T Crocker; Mary Beth Corcoran; Jerry Yoder; William E Haley; Hongbin Chen; David Boulware; Lodovico Balducci Journal: Crit Rev Oncol Hematol Date: 2004-01 Impact factor: 6.312
Authors: Anna Z de Boer; Willemien van de Water; Esther Bastiaannet; Nienke A de Glas; Mandy Kiderlen; Johanneke E A Portielje; Martine Extermann Journal: Breast Cancer Res Treat Date: 2020-08-19 Impact factor: 4.872